Olympiad Research LP Takes Position in Cigna Group $CI

Olympiad Research LP bought a new position in shares of Cigna Group (NYSE:CI) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 660 shares of the health services provider’s stock, valued at approximately $218,000.

Other institutional investors have also made changes to their positions in the company. Flaharty Asset Management LLC purchased a new position in Cigna Group in the first quarter valued at about $28,000. 1248 Management LLC bought a new stake in shares of Cigna Group in the 1st quarter valued at approximately $29,000. Solstein Capital LLC bought a new position in shares of Cigna Group in the second quarter worth about $29,000. Chilton Capital Management LLC acquired a new position in shares of Cigna Group during the 2nd quarter worth about $30,000. Finally, Activest Wealth Management boosted its stake in Cigna Group by 360.0% during the 1st quarter. Activest Wealth Management now owns 92 shares of the health services provider’s stock valued at $30,000 after purchasing an additional 72 shares during the period. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Brian C. Evanko sold 5,368 shares of Cigna Group stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the completion of the sale, the insider directly owned 51,182 shares of the company’s stock, valued at approximately $15,354,600. This trade represents a 9.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David Cordani acquired 4,134 shares of the stock in a transaction on Monday, November 3rd. The shares were purchased at an average price of $241.88 per share, for a total transaction of $999,931.92. Following the transaction, the chief executive officer directly owned 157,935 shares in the company, valued at approximately $38,201,317.80. This trade represents a 2.69% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.70% of the stock is owned by corporate insiders.

Cigna Group Price Performance

Shares of NYSE CI opened at $269.52 on Friday. The stock has a market capitalization of $72.00 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 0.88 and a beta of 0.44. Cigna Group has a fifty-two week low of $239.51 and a fifty-two week high of $350.00. The business has a 50-day moving average of $289.75 and a 200-day moving average of $301.38. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.71 and a quick ratio of 0.71.

Cigna Group (NYSE:CI) last released its earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating the consensus estimate of $7.64 by $0.19. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The business had revenue of $69.57 billion during the quarter, compared to analysts’ expectations of $66.40 billion. During the same period last year, the business earned $7.51 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. As a group, sell-side analysts predict that Cigna Group will post 29.77 earnings per share for the current fiscal year.

Cigna Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, December 4th will be issued a dividend of $1.51 per share. The ex-dividend date of this dividend is Thursday, December 4th. This represents a $6.04 annualized dividend and a dividend yield of 2.2%. Cigna Group’s payout ratio is presently 26.64%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CI. The Goldman Sachs Group cut their price objective on shares of Cigna Group from $370.00 to $330.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Cowen restated a “buy” rating on shares of Cigna Group in a research note on Tuesday, November 4th. TD Cowen reduced their price objective on Cigna Group from $387.00 to $333.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Guggenheim dropped their price objective on Cigna Group from $350.00 to $309.00 in a report on Friday, October 31st. Finally, Cantor Fitzgerald decreased their target price on Cigna Group from $365.00 to $325.00 in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Cigna Group has a consensus rating of “Moderate Buy” and an average price target of $334.05.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.